Data on the optimization of a GC-MS procedure for the determination of total plasma myo-inositol.

Myo-inositol (MI) is one of the stereoisomers of hexahydroxycyclohexane, which plays an important role in intracellular signal pathway. Derivatization is an indispensable step in both external and internal standard method during the chromatography-mass spectrometer (GC-MS) detection, as MI can't be ionized directly. It is valuable to optimize the derivative process and the detection volume for clinical detection. This article contains optimization data related to research publication "Quantification of plasma myo-inositol using gas chromatography-mass spectrometry" [1]. Here we introduce the data on the optimized derivatization volume, temperature, duration and the detection volume.

Quantification of plasma myo-inositol using gas chromatography-mass spectrometry.

BACKGROUND: Myo-inositol (MI) deficiency is associated with an increased risk for neural tube defects (NTDs), mental disorders and metabolic diseases. We developed a gas chromatography-mass spectrometry (GC-MS) method to detect MI in human plasma, which was accurate, relatively efficient and convenient for clinical application. METHODS: An external standard method was used for determination of plasma MI. Samples were analyzed by GC-MS after derivatization. The stable-isotope labeled internal standard approach was used to validate the method's accuracy. Alpha fetal protein (AFP) was detected by chemiluminescence immunoassay. RESULTS: The method was validated by determining the linearity, sensitivity and recovery rate. There was a good agreement between the internal standard approach and the present method. The NTD-affected pregnancies showed lower plasma MI (P=0.024) and higher AFP levels (P=0.001) than control. Maternal MI level showed a better discrimination in spina bifida subgroup, while AFP level showed a better discrimination in anencephaly subgroup after stratification analysis. CONCLUSIONS: We developed a sensitive and reliable method for the detection of clinical plasma MI, which might be a marker for NTDs screening, and established fundamental knowledge for clinical diagnosis and prevention for the diseases related to disturbed MI metabolism.